|Day Low/High||20.49 / 20.95|
|52 Wk Low/High||11.41 / 21.36|
The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 1,401,809 share decrease in total short interest for Halozyme Therapeutics Inc , to 10,232,867, a decrease of 12.05% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.
Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.
In recent trading, shares of Halozyme Therapeutics Inc have crossed above the average analyst 12-month target price of $20.11, changing hands for $20.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
CONTINUES TO EXPECT TARGET NUMBER OF PFS EVENTS IN HALO-301 REGISTRATION TRIAL TO BE REACHED IN LATE Q4
Jim Cramer focuses on Roku, Sierra Wireless, Visa, Cimarex Energy, First Solar, Halozyme Therapeutics.
Don't buy big here and don't buy all at once, but it's not too late to ride this bull to profits, says Jim Cramer.
The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Halozyme Therapeutics, Inc.
Jim Cramer is bullish on Exxon, Chevron, Cimarex Energy, Skechers USA, and Halozyme Therapeutics.
Jim Cramer says President Trump has been a great salesman, but when we look at winning stocks, it's the strong CEOs who are driving success.
-- Subcutaneous injection has potential to reduce multi-hour infusion to 5-minutes--
The Henderson, Nev.-based company said interim data from a Phase 2 study showed an objective response rate of 73%.
PEGPH20, atezolizumab Combination to be Evaluated Under Clinical Collaboration
In this sometimes fickle market, supply and demand are still at play.
Proposals are having an effect ahead of afternoon announcement.
It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.
The indices may need a rest, but stock-pickers have an edge.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.